Matinas Biopharma (MTNB) Competitors $0.81 -0.05 (-5.97%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$0.81 0.00 (-0.37%) As of 05/30/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTNB vs. TRIB, COCP, RLYB, ERNA, ABP, EDSA, MBRX, UBX, MEIP, and UPXIShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Trinity Biotech (TRIB), Cocrystal Pharma (COCP), Rallybio (RLYB), Eterna Therapeutics (ERNA), Abpro (ABP), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Unity Biotechnology (UBX), MEI Pharma (MEIP), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Trinity Biotech Cocrystal Pharma Rallybio Eterna Therapeutics Abpro Edesa Biotech Moleculin Biotech Unity Biotechnology MEI Pharma Upexi Matinas Biopharma (NYSE:MTNB) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do institutionals & insiders have more ownership in MTNB or TRIB? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MTNB or TRIB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is MTNB or TRIB more profitable? Matinas Biopharma has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Trinity Biotech -34.39%N/A -21.37% Which has more volatility and risk, MTNB or TRIB? Matinas Biopharma has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Does the media prefer MTNB or TRIB? In the previous week, Trinity Biotech had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Matinas Biopharma. Trinity Biotech's average media sentiment score of 1.44 beat Matinas Biopharma's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Overall Sentiment Matinas Biopharma Neutral Trinity Biotech Positive Which has stronger valuation and earnings, MTNB or TRIB? Matinas Biopharma has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M3.76-$22.94M-$3.86-0.21Trinity Biotech$61.56M0.19-$24.02M-$2.82-0.22 Does the MarketBeat Community prefer MTNB or TRIB? Trinity Biotech received 335 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/ATrinity BiotechOutperform Votes33569.79% Underperform Votes14530.21% SummaryTrinity Biotech beats Matinas Biopharma on 9 of the 15 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.13M$6.58B$5.42B$19.49BDividend YieldN/A2.63%5.28%3.89%P/E Ratio-0.178.7327.0534.81Price / Sales3.76238.78406.3039.19Price / CashN/A65.8538.2517.51Price / Book0.186.336.744.74Net Income-$22.94M$144.21M$3.23B$1.02B7 Day PerformanceN/A1.06%1.22%1.30%1 Month Performance30.97%-0.45%5.99%4.79%1 Year PerformanceN/A-2.06%25.78%5.33% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.81-6.0%N/AN/A$4.13M$1.10M-0.1730Gap UpTRIBTrinity Biotech1.8469 of 5 stars$0.82-3.2%N/A-62.3%$14.80M$59.13M-0.36480Positive NewsUpcoming EarningsShort Interest ↓COCPCocrystal Pharma2.598 of 5 stars$1.41-0.7%$7.00+396.5%-24.4%$14.44MN/A-0.7610News CoveragePositive NewsShort Interest ↑Analyst RevisionRLYBRallybio2.6748 of 5 stars$0.35-0.9%$10.00+2,781.8%-81.2%$14.44M$848,000.00-0.2240ERNAEterna Therapeutics0.7182 of 5 stars$0.23+2.7%N/A-88.2%$14.34M$582,000.00-0.0310Short Interest ↑ABPAbproN/A$0.27+18.3%$4.00+1,370.6%N/A$14.20M$183,000.000.0015Gap UpHigh Trading VolumeEDSAEdesa Biotech2.9081 of 5 stars$2.01-1.0%$21.00+944.8%-53.8%$14.12MN/A-1.0720Short Interest ↓Gap DownMBRXMoleculin Biotech1.9835 of 5 stars$0.99+5.7%$6.00+503.9%-81.2%$14.04MN/A0.0020Short Interest ↑UBXUnity Biotechnology4.3816 of 5 stars$0.81-1.3%$4.25+425.3%-56.1%$13.93M$240,000.00-0.6260News CoverageAnalyst ForecastAnalyst RevisionMEIPMEI Pharma2.0648 of 5 stars$2.08flatN/A-22.0%$13.85M$65.30M-0.36100Gap DownUPXIUpexi1.443 of 5 stars$9.64-5.4%N/A-10.3%$13.75M$18.63M0.00130News CoverageAnalyst UpgradeShort Interest ↓ Related Companies and Tools Related Companies TRIB Alternatives COCP Alternatives RLYB Alternatives ERNA Alternatives ABP Alternatives EDSA Alternatives MBRX Alternatives UBX Alternatives MEIP Alternatives UPXI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTNB Stock Free MTNB Stock Alerts